RxDoctor Payments Data

Aaron Friedman

Metairie, LANPI 1194751925

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $7,570 of the $11,274 with a category attached, or 67.1%. AbbVie accounts for 82.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2020 at $7,254 and has fallen 99.2% since, to $59 in 2025.

$11,274in general payments, 2019–2025

Across 162 payments — averaging $69.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$506
  • Biohaven Pharmaceuticals, Inc.$269
  • Biohaven Pharmaceutical Holding Company Ltd.$254
  • Amgen$168
  • Medtronic$125
  • plus $623 from 15 others

What the payments were for

  • Speaking & faculty fees$7,57067%
  • Travel & lodging$5565%
  • Food & beverage$3,14828%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →